Subtopic Deep Dive
Post-Transplant Lymphoproliferative Disorder
Research Guide
What is Post-Transplant Lymphoproliferative Disorder?
Post-Transplant Lymphoproliferative Disorder (PTLD) is a spectrum of lymphoid proliferations ranging from polyclonal hyperplasia to aggressive lymphoma occurring in immunosuppressed transplant recipients, primarily driven by Epstein-Barr virus (EBV) reactivation.
PTLD affects solid organ and hematopoietic stem cell transplant patients, with incidence elevated 11.8-fold in renal recipients over 10 years (Opelz and Döhler, 2004, 1066 citations). Most cases are EBV-positive B-cell disorders classified into categories based on morphology and clonality (Knowles et al., 1995, 593 citations). Rituximab-based therapies improved outcomes, as reviewed across 20 years of experience (Salles et al., 2017, 583 citations).
Why It Matters
PTLD causes high morbidity in transplant patients, with OKT3 immunosuppression linked to sudden incidence spikes in cardiac recipients (Swinnen et al., 1990, 948 citations). EBV drives PTLD pathogenesis, with >90% global infection rate enabling tumor development in vulnerable hosts (Thompson and Kurzrock, 2004, 789 citations). Rituximab monotherapy or with chemotherapy enhances survival, informing personalized regimens (Dierickx and Habermann, 2018, 437 citations). Research guides prevention via EBV monitoring and reduced immunosuppression (Gottschalk et al., 2004, 488 citations).
Key Research Challenges
EBV Latency Heterogeneity
PTLD spans EBV-driven polyclonal to monoclonal lesions, complicating regression predictions post-immunosuppression reduction (Knowles et al., 1995). Latency patterns vary, affecting therapeutic targeting (Thompson and Kurzrock, 2004). Over 200,000 transplant cases show variable risks by organ type (Opelz and Döhler, 2004).
Immunosuppression Balancing
Reducing immunosuppression risks graft rejection while enabling PTLD regression in early cases (Gottschalk et al., 2004). OKT3 use tripled PTLD incidence in cardiac transplants (Swinnen et al., 1990). Optimal regimens remain undefined across transplant types (Dierickx and Habermann, 2018).
Rituximab Response Prediction
Rituximab efficacy varies by PTLD category and EBV status, requiring prognostic markers (Salles et al., 2017). Polyclonal lesions regress more readily than monoclonal lymphomas (Knowles et al., 1995). Long-term data from large cohorts needed for personalization (Opelz and Döhler, 2004).
Essential Papers
The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms
Rita Alaggio, Catalina Amador, Ioannis Anagnostopoulos et al. · 2022 · Leukemia · 3.3K citations
Lymphomas After Solid Organ Transplantation: A Collaborative Transplant Study Report
Gerhard Opelz, Bernd Döhler · 2004 · American Journal of Transplantation · 1.1K citations
We used the Collaborative Transplant Study database to analyze the incidence, risk, and impact of malignant lymphomas in approximately 200,000 organ transplant recipients. Over a 10-year period, th...
Increased Incidence of Lymphoproliferative Disorder after Immunosuppression with the Monoclonal Antibody OKT3 in Cardiac-Transplant Recipients
Lode J. Swinnen, Maria Rosa Costanzo‐Nordin, Susan G. Fisher et al. · 1990 · New England Journal of Medicine · 948 citations
A sudden increase in the incidence of post-transplantation lymphoproliferative disorder among the patients in our cardiac-transplantation program was temporally related to introduction of the immun...
Epstein-Barr Virus and Cancer
Matthew P. Thompson, Razelle Kurzrock · 2004 · Clinical Cancer Research · 789 citations
Abstract EBV was the first human virus to be directly implicated in carcinogenesis. It infects >90% of the world’s population. Although most humans coexist with the virus without serious seq...
Correlative morphologic and molecular genetic analysis demonstrates three distinct categories of posttransplantation lymphoproliferative disorders
DM Knowles, Ethel Cesarman, Amy Chadburn et al. · 1995 · Blood · 593 citations
Abstract The posttransplantation lymphoproliferative disorders (PT-LPDs) are a morphologically heterogeneous group of Epstein-Barr virus (EBV)-driven lymphoid proliferations of varying clonal compo...
Rituximab in B-Cell Hematologic Malignancies: A Review of 20 Years of Clinical Experience
Gilles Salles, Martin Barrett, Robin Foà et al. · 2017 · Advances in Therapy · 583 citations
F. Hoffmann-La Roche Ltd., Basel, Switzerland.
Post-Transplant Lymphoproliferative Disorders
Stephen Gottschalk, Cliona M. Rooney, Helen E. Heslop · 2004 · Annual Review of Medicine · 488 citations
Post-transplant lymphoproliferative disorder (PTLD) is a life-threatening complication after hematopoietic stem cell or solid organ transplantation. The majority of PTLD is of B-cell origin and ass...
Reading Guide
Foundational Papers
Start with Opelz and Döhler (2004) for incidence data across 200,000 transplants, Swinnen et al. (1990) for OKT3 risks, and Knowles et al. (1995) for PTLD categorization, establishing epidemiology and pathology basics.
Recent Advances
Study Dierickx and Habermann (2018) for adult management, Alaggio et al. (2022) for WHO lymphoid updates, and Shannon-Lowe and Rickinson (2019) for EBV tumor landscape.
Core Methods
Core techniques include EBV PCR monitoring, morphologic WHO grading, clonality PCR/ISH, and rituximab ± chemotherapy; molecular genetics distinguish PTLD categories (Knowles et al., 1995; Salles et al., 2017).
How PapersFlow Helps You Research Post-Transplant Lymphoproliferative Disorder
Discover & Search
Research Agent uses searchPapers('Post-Transplant Lymphoproliferative Disorder PTLD EBV') to retrieve 250M+ OpenAlex papers, then citationGraph on Opelz and Döhler (2004) reveals 1066-citation impact and linked incidence studies. findSimilarPapers expands to OKT3 risks (Swinnen et al., 1990), while exaSearch queries 'PTLD rituximab outcomes post-2015' for recent advances like Alaggio et al. (2022).
Analyze & Verify
Analysis Agent employs readPaperContent on Dierickx and Habermann (2018) to extract rituximab protocols, verifies claims via CoVe against Opelz database stats, and runs PythonAnalysis(pandas) to plot PTLD incidence rates from Gottschalk et al. (2004) abstracts. GRADE grading scores evidence from 10 papers as high for EBV association (Thompson and Kurzrock, 2004) but moderate for prognostic markers.
Synthesize & Write
Synthesis Agent detects gaps in OKT3-era prevention via contradiction flagging between Swinnen (1990) and modern rituximab data (Salles et al., 2017), then Writing Agent uses latexEditText for PTLD review sections, latexSyncCitations for 20-paper bibliography, and latexCompile for camera-ready manuscript. exportMermaid generates pathway diagrams of EBV latency to PTLD categories (Knowles et al., 1995).
Use Cases
"Analyze PTLD incidence trends from Opelz 2004 dataset using Python."
Research Agent → searchPapers('Opelz Döhler 2004 PTLD') → Analysis Agent → readPaperContent + runPythonAnalysis(pandas/matplotlib on incidence data) → researcher gets CSV-exported survival curves and statistical p-values.
"Draft LaTeX review on rituximab in PTLD with citations."
Synthesis Agent → gap detection on Salles 2017 + Dierickx 2018 → Writing Agent → latexGenerateFigure(rituximab flowchart) → latexSyncCitations(10 PTLD papers) → latexCompile → researcher gets PDF manuscript with auto-generated bibliography.
"Find code for EBV genome analysis in PTLD papers."
Research Agent → paperExtractUrls(Thompson Kurzrock 2004) → Code Discovery → paperFindGithubRepo → githubRepoInspect → researcher gets annotated GitHub repos with EBV sequencing pipelines linked to PTLD studies.
Automated Workflows
Deep Research workflow scans 50+ PTLD papers via searchPapers → citationGraph → structured report with GRADE-scored sections on EBV risks (Opelz and Döhler, 2004). DeepScan applies 7-step CoVe to verify rituximab efficacy claims across Swinnen (1990) and Salles (2017), outputting checkpoint-validated summary. Theorizer generates hypotheses on immunosuppression minimization from Knowles (1995) categories and recent WHO updates (Alaggio et al., 2022).
Frequently Asked Questions
What defines Post-Transplant Lymphoproliferative Disorder?
PTLD comprises EBV-driven B-cell proliferations in transplant recipients under immunosuppression, spanning polyclonal hyperplasia to monoclonal lymphoma (Knowles et al., 1995; Gottschalk et al., 2004).
What are main PTLD diagnostic methods?
Diagnosis uses morphology, EBV detection, and clonality assays; WHO 5th edition refines categories (Alaggio et al., 2022). Molecular analysis distinguishes regression-prone from aggressive forms (Knowles et al., 1995).
What are key PTLD papers?
Opelz and Döhler (2004, 1066 citations) quantify incidence; Swinnen et al. (1990, 948 citations) link OKT3 to risks; Salles et al. (2017, 583 citations) review rituximab.
What open problems exist in PTLD research?
Prognostic markers for rituximab response, optimal immunosuppression reduction, and EBV-negative PTLD mechanisms remain unresolved (Dierickx and Habermann, 2018; Thompson and Kurzrock, 2004).
Research Viral-associated cancers and disorders with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Post-Transplant Lymphoproliferative Disorder with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers